Laboratory Corporation of America Holdings (NYSE:LH) insider Lisa J. Uthgenannt sold 5,000 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $160.00, for a total value of $800,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at 158.65 on Friday. The firm has a 50-day moving average of $151.97 and a 200 day moving average of $143.06. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The firm has a market capitalization of $16.25 billion, a P/E ratio of 22.22 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.47 billion. During the same quarter in the previous year, the business posted $2.36 EPS. The firm’s revenue was up 4.9% on a year-over-year basis. On average, equities research analysts expect that Laboratory Corporation of America Holdings will post $9.50 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Laboratory Corporation of America Holdings (NYSE:LH) Insider Sells $800,000.00 in Stock” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/06/insider-selling-laboratory-corporation-of-america-holdings-nyselh-insider-sells-800000-00-in-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Laboratory Corporation of America Holdings by 3,602.5% in the first quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock valued at $1,158,430,000 after buying an additional 7,856,297 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Laboratory Corporation of America Holdings by 139.4% in the first quarter. JPMorgan Chase & Co. now owns 677,069 shares of the medical research company’s stock valued at $97,139,000 after buying an additional 394,247 shares during the last quarter. Bessemer Group Inc. boosted its position in shares of Laboratory Corporation of America Holdings by 43.6% in the second quarter. Bessemer Group Inc. now owns 1,288,017 shares of the medical research company’s stock valued at $198,535,000 after buying an additional 391,145 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its position in shares of Laboratory Corporation of America Holdings by 901.1% in the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 335,545 shares of the medical research company’s stock valued at $8,748,000 after buying an additional 302,028 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Laboratory Corporation of America Holdings by 139.9% in the first quarter. Teachers Advisors LLC now owns 445,372 shares of the medical research company’s stock valued at $63,898,000 after buying an additional 259,709 shares during the last quarter. Institutional investors own 91.58% of the company’s stock.

LH has been the topic of a number of analyst reports. Craig Hallum reissued a “buy” rating and issued a $179.00 price target (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research report on Thursday, July 27th. Credit Suisse Group restated a “buy” rating and issued a $146.00 price objective on shares of Laboratory Corporation of America Holdings in a report on Sunday, May 28th. BidaskClub upgraded shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. ValuEngine lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. Finally, Jefferies Group LLC decreased their target price on shares of Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating for the company in a research note on Friday, April 28th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $158.42.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.